A systematic method for estimating individual responses to treatment with antipsychotics in CATIE

Center for Biomarker Research and Personalized Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond VA, USA.
Schizophrenia Research (Impact Factor: 4.43). 11/2008; 107(1):13-21. DOI: 10.1016/j.schres.2008.09.009
Source: PubMed

ABSTRACT In addition to comparing drug treatment groups, the wealth of genetic and clinical data collected in the Clinical Antipsychotic Trials of Intervention Effectiveness study offers tremendous opportunities to study individual differences in response to treatment with antipsychotics. A major challenge, however, is how to estimate the individual responses to treatments. For this purpose, we propose a systematic method that condenses all information collected during the trials in an optimal, empirical fashion.
Our method comprises three steps. First, we test how to best model treatment effects over time. Next, we screen many covariates to select those that will further improve the precision of the individual treatment effect estimates which, for example, improves power to detect predictors of individual treatment response. Third, Best Linear Unbiased Predictors (BLUPs) of the random effects are used to estimate for each individual a treatment effect based on the model empirically indicated to best fit the data. We illustrate our method for the Positive and Negative Syndrome Scale (PANSS).
A model assuming it takes on average about 30 days for a treatment to exert an effect that will then remain about the same for the rest of the trial showed the best fit to the data. Of all screened covariates, only two improved the precision of the individual treatment effect estimates. Finally, correlations between drug effects and PANSS scales suggested that in CATIE it cannot be recommended to simply combine treatment effects across drugs (e.g. to study common drug mechanisms), but it is sensible to study how a given drug affects multiple symptom dimensions.
We demonstrate that treatment effects can be estimated in a way that condenses all information collected in an optimal, empirical fashion. We expect the proposed method to be valuable for other clinical outcomes in CATIE and potentially other clinical trials.

Download full-text


Available from: Joseph L. McClay, Jul 07, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Suicide and violence often co-occur in the general population as well as in mentally ill individuals. Few studies, however, have assessed whether these suicidal behaviors are predictive of violence risk in mental illness. The aim of this study is to investigate whether suicidal behaviors, including suicidal ideation, threats, and attempts, are significantly associated with increased violence risk in individuals with schizophrenia. Data for these analyses were obtained from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial, a randomized controlled trial of antipsychotic medication in 1460 adults with schizophrenia. Univariate Cox regression analyses were used to calculate hazard ratios (HRs) for suicidal ideation, threats, and attempts. Multivariate analyses were conducted to adjust for common confounding factors, including: age, alcohol or drug misuse, major depression, antisocial personality disorder, depression, hostility, positive symptom, and poor impulse control scores. Tests of discrimination, calibration, and reclassification assessed the incremental predictive validity of suicidal behaviors for the prediction of violence risk. Suicidal threats and attempts were significantly associated with violence in both males and females with schizophrenia with little change following adjustment for common confounders. Only suicidal threats, however, were associated with a significant increase in incremental validity beyond age, diagnosis with a comorbid substance use disorder, and recent violent behavior. Suicidal threats are independently associated with violence risk in both males and females with schizophrenia, and may improve violence risk prediction.
    Schizophrenia Research 02/2014; 154(1-3). DOI:10.1016/j.schres.2014.02.001 · 4.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Multiport Array Receptor (MAR), a system which combines optical sensing with integrated focal-plane processing capabilities, is described. Its central element is a photosensor array with hexagonal tesselation and complex peripheral selection logic which provides parallel analog readout over prescribed areas. An external computing module performs real-time spatial convolution at multiple resolutions while a closed-loop microprogrammed controller addresses regions of interest and supervises communication between the camera and the host computer. This integrated image sensor and processor implements programmed sequences of instruction primitives and yields a complete state description of each processed pixel. It is capable of automatic edge tracking and returns lists of connected pixels
    Pattern Recognition, 1990. Proceedings., 10th International Conference on; 07/1990
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The regional neuronal changes taking place in the early and late stages of antipsychotic treatment are still not well characterized in humans. In addition, it is not known whether these regional changes are predictive or correlated with treatment response. Using PET with 15O, we evaluated the time course of regional cerebral blood flow (rCBF) patterns generated by a first (haloperidol) and a second (olanzapine) generation antipsychotic drug (APD) in patients with schizophrenia during a 6 week treatment trial. Patients were initially scanned after withdrawal of all psychotropic medication (two weeks), and then blindly randomized to treatment with haloperidol (n=12) or olanzapine (n=17) for a period of 6 weeks. Patients were scanned again after 1 and 6 weeks of treatment. All assessments, including scanning sessions, were obtained in a double-blind manner. As hypothesized, we observed rCBF changes that were common to both drugs, implicating cortico-subcortical and limbic neuronal networks in antipsychotic action. In addition, in these regions, some patterns seen at week 1 and 6 were distinctive, indexing neuronal changes related to an early (ventral striatum, hippocampus) and consolidated [anterior cingulate/medial frontal cortex (ACC/MFC)] stage of drug response. Finally, both after 1 and 6 weeks of treatment, we observe differential patterns of rCBF activation between good and poor responders. After one week of treatment, greater rCBF increase in ventral striatum and greater decrease in hippocampus were associated with good response.
    Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 09/2009; 34(13):2675-90. DOI:10.1038/npp.2009.94 · 7.83 Impact Factor